Bordeaux

• Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamo … Recruiting
  2023-506308-24-00 10 2024-05-22 Recurrent or metastatic head and neck squamous cell carcinoma
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CD … Recruiting
  2023-506888-34-00 1 2024-05-22 Advanced or metastatic solid tumors including hormone receptor positiv
• A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants with Chronic Mye … Recruiting
  2023-507677-18-00 9 2024-05-17 Chronic Myeloid Leukemia
• UVB: treatment of UVeitis in Behçet’s diseases with biologic Recruiting
  2024-513371-41-00 4 2024-04-25 Severe uveitis of Behçet’s disease
• Gut microbiome intervention with EXL01 in combination with nivolumab and FOLFOX as first-line treatment for patients with PD-L1 CPS ≥5 metas … Recruiting
  2023-506753-38-00 4 2024-04-16 metastatic gastric adenocarcinoma
• Evaluation of EXL01 a new Live Biotherapeutic Product to prevent recurrence of Clostridioides difficile infection in high-risk patients. LIV … Recruiting
  2023-506232-32-00 9 2024-04-08 Multiple recurrences of Clostridioides difficile infection treated wit
• A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participa … Recruiting
  2023-503208-94-00 6 2024-04-04 Prostate cancer
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer
• PLGG – MEKTRIC (Pediatric Low Grade Glioma – MEKinhibitor TRIal vs Chemotherapy) Recruiting
  2023-508531-30-00 4 2024-03-25 grade 1 glioma/mixed glio-neuronal tumors or pleomorphic xanthoastrocy
• Efficacy of 7 days versus 14 days of antibiotic therapy for acute pyelonephritis in kidney transplant recipients Recruiting
  2024-513328-40-00 6 2024-03-25 Pyelonephritis
• A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease (PASADENA) Recruiting
  2023-504472-24-00 4 2024-03-19 Early Idiopathic Parkinson’s disease (PD)
• CAPSAPED Recruiting
  2022-500265-27-00 5 2024-03-05 Chronic postchirurgical or post-traumatic neuropathic pain
• OPtimisation of antiviral Therapy in Immunocompromised COVID-19 patients: a randomized factorial controlled strategy trial: the OPTICOV Stud … Recruiting
  2022-501408-81-01 4 2024-03-04 Covid-19
• RECOVERY Recruiting
  2023-507441-29-00 5 2024-02-29 Pneumonia
• An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi … Recruiting
  2022-501453-36-00 5 2024-02-23 Breast cancer
• Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib … Recruiting
  2023-503708-10-00 5 2024-02-20 Locally advanced or metastatic breast cancer
• Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors Recruiting
  2023-506604-18-00 1 2024-02-14 Triple negative breast cancer
• Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU) Recruiting
  2024-516402-32-00 5 2024-02-13 Adult patients with aHUS associated with HE and severe kidney involvem
• CUSTOMIZED ANTIBIOTIC TREATMENT DURATION AMONG HOSPITALIZED PATIENTS WITH MODERATELY SEVERE COMMUNITY-ACQUIRED PNEUMONIA [CAT-CAP] Recruiting
  2023-504208-27-00 5 2024-02-12 Community-acquired pneumonia
• A study to evaluate the effects and safety of INCA033989 in participants with myelofibrosis or essential thrombocythemia Recruiting
  2022-502514-86-00 1 2024-02-07 Myeloproliferative Neoplasms
• Alpelisib for the treatment of lymphatic malformations associated with a PIK3CA mutation Recruiting
  2023-504146-60-00 10 2024-02-07 lymphatic malformations associated with PIK3CA mutation
• Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults with Active Sjögren’s Syndrome Recruiting
  2023-503327-26-00 5 2024-01-31 Sjogren's syndrome
• FIRST IN-HUMAN STUDY EVALUATING THE EFFECT OF VARIOUS DOSES OF ODM-212 IN SUBJECTS WITH SELECTED ADVANCED SOLID TUMOURS Recruiting
  2022-503061-29-00 7 2024-01-22 Neoplasms benign malignant and unspecified (incl cysts and polyps). Me
• A study of STX-478 alone and in combination with other anticancer drugs in participants with advanced solid tumors. Recruiting
  2023-504807-94-00 7 2023-12-26 Breast Cancer; Advanced solid tumors including but not limited to gyne

Showing 433–456 of 1,096 trials